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Protein kinase Emk1/Par1 (GenBank accession no. X97630) has been identified as a regulator of the immune system homeostasis. Since
immunological factors are critical for the development of chronic allograft nephropathy (CAN), we reasoned that expression of Par1/Emk1
could be altered in kidney allografts undergoing CAN. In this paper, we have analysed the association among renal allograft lesions and
expression of Par1/Emk1, studied by RT-PCR on total RNA from 51 protocol biopsies of transplanted kidneys, five normal kidneys, and five
dysfunctional allografts. The most significant result obtained has been the detection of alterations in the normal pattern of alternative splicing
of the Par1/Emk1 transcript, alterations that included loss of expression of constitutively expressed isoforms, and the inclusion of a cryptic
exon to generate a new Emk1 isoform (Emk1C). Expression of Emk1C was associated with an increase in the extension of the interstitial
infiltrate (0.88F 0.33 in Emk1C[+] vs. 0.41F 0.50 in Emk1C[  ]; P < 0.011), and with a trend to display higher interstitial scarring
(0.66F 0.70 vs. 0.29F 0.52; P= 0.09) in protocol biopsies when evaluated according to the Banff schema. Moreover, a higher mean arterial
pressure (MAP) was also observed (110F 11 vs. 99F 11 mm Hg; P= 0.012). From these results we propose that Par1/Emk1 could have a
role in the development of CAN in kidney allografts.
D 2004 Elsevier B.V. All rights reserved.Keywords: Kidney allograft; Banff 97 schema; Protocol biopsy; Chronic allograft nephropathy (CAN); ser/thr protein kinase Par1/Emk1; Splicing alteration;
Cryptic exon
1. Introduction rently, new techniques of molecular biology are being appliedChronic allograft nephropathy (CAN) is the main cause
for late graft loss, and although its ethiopathogenics is not yet
well understood, immunological factors seem to play a
critical role in its development [1]. Early diagnosis of CAN
is important to establish therapeutic strategies that improve
allograft survival [2]. In this sense, protocol biopsies of renal
allografts are currently being used as early warning tools to
detect the first signs of allograft dysfunction [3], although
further improvements are needed to assess early protocol
allograft biopsies, and to increase their clinical utility. Cur-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.01.008
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E-mail address: enavarro@iro.es (E. Navarro).to the study of protocol biopsies with the aim to detect and
characterize genes that could be useful either to understand
the molecular mechanisms responsible for renal diseases, or
to identify new surrogate markers that might precede histo-
logical lesions, and hence that could be used in diagnostic
procedures [4,5]. In this sense, high-density DNA arrays
facilitate the simultaneous expression analysis of many
different genes, whose involvement in the development of
renal pathologies can be further studied using the new tools of
functional genomics and knock-out mice model [6].
Ser/thr protein kinase Emk1/Par1 (GenBank accession
no. X97630) has been identified as a key regulator of
immune system homeostasis, specially of T and B cell
function [7]. In a recent paper, Emk1 / null mutant mice
were shown to display a complex phenotype with two
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T lymphocytes from Emk1 / mice showed a deregulated
surface expression of CD44 and CD62L, as well as an
overproduction of IFN-g, while kidneys from Emk1 /
mice showed a lymphocyte infiltrate that could be the
consequence of an autoimmune reaction or of defects in
homing and cell adhesion of kidney cells or lymphocytes
[7].
We recently cloned the human form of Emk1 and
described the presence of Emk1 isoforms that differed in
their 5V end (Emk1A and Emk1B), and in the use of
alternative exon 16, whose regulated splicing originated
other two Emk1 isoforms, Emk1D and Emk1E [8,9]. Given
that Emk1 / null mutant mice displayed gross phenotypic
abnormalities in kidneys and lymphocytes, and that no data
are currently available on the alterations of Emk1 expression
in transplanted organs, we have studied the pattern of Emk1
expression in renal protocol biopsies of transplanted patients
with stable function. Our aim was to detect alterations that
could be associated with the early development of renal
lesions.2. Materials and methods
2.1. Patients
Our group has been performing protocol renal biopsies in
stable grafts during the first year of follow-up, with the aim
to characterize early renal damage and the molecular mech-
anisms involved in its development [3,10]. In the present
study, we analysed data from a cohort of protocol biopsies
and from five diagnostic biopsies, from which total RNA
was available. Normal control tissues were obtained from
five patients undergoing nephrectomy because of renal
tumours. These studies were approved by the Hospital
Ethics Committee, and written informed consent from the
patients were obtained in all the cases.
2.2. Definition of clinical variables
The following variables were evaluated for each patient:
age and sex of recipient, age of donor, degree of HLA
matching (total number of mismatches in the A, B and DR
loci), presence of panel-reactive antibodies over 20%, cold
ischemia time (CIT), and immunosuppressive treatment
used. After transplantation, the following variables were
also assessed: acute tubular necrosis, acute rejection, serum
creatinine, proteinuria, mean arterial pressure (MAP),
number of antihypertensive drugs at the time of biopsy,
evolution of serum creatinine and proteinuria during fol-
low-up, and mean CsA dose and CsA levels until renal
biopsy.
Post-transplant acute tubular necrosis was defined as the
need for haemodialysis during the first week after surgery,
once an alternative diagnosis was ruled out (e.g., hyperacute or accelerated rejection). Acute rejection was defined
as an acute rise in serum creatinine that was subsequently
treated. Immunosuppressive regimens employed were the
following: (a) CsA in monotherapy (n = 2); (b) triple
standard regimen with CsA, azathioprine and PDN
(n = 13); (c) concomitant induction therapy with antilym-
phocytic antibodies, CsA and PDN (n = 21); (d) triple
regimen with CsA, mycophenolate mofetil (MMF) and
PDN (n = 13); (e) concomitant induction therapy with
antilymphocytic antibodies, MMF and PDN without CsA
(n = 2). Modifications of CsA doses were performed con-
sidering the whole blood CsA trough levels measured by
radio immunoassay with an anti-CsA monoclonal antibody
(CYCLO-Trac-SP, Incstar, Stillwater, MN). Mean CsA
dose and levels received were calculated from CsA dose
and measured levels at days 7, 14, 30, 60, 90, and the day
of the biopsy.
2.3. Histological study of biopsies
Renal biopsies, either protocol or diagnostic, were
performed with a spring-loaded, 16-gauge, gun (Pro-Mag
2.2; Manan Medical Products, Northbrook, IL) with ultra-
sound guidance. Additionally, we obtained control biopsies
from histologically normal, nephrectomized tissues before
vascular clamping. For all the biopsies, two cores of tissue
were obtained, one of them was processed for conventional
histological staining as previously described [3], while the
second one was immediately snap-frozen in liquid nitrogen
and stored at  80 jC for RNA extraction. Renal acute
and chronic lesions were scored according to the 1997
Banff working classification criteria [11]. For immunohis-
tochemical studies, paraffin-embedded specimens from
available samples were sliced at 4 Am, incubated with
mouse monoclonal antibodies against human CD3 (clone
PS1; Novocastra, Newcastle, UK), CD20 (clone L26;
Master Diagno´stica SL, Granada, Spain), and CD68 (clone
KP1; Master Diagno´stica), and subsequently stained with a
goat-antimouse secondary antibody labelled with horserad-
ish peroxidase (Envision SystemR, Dako) in an automated
immunohistochemical stainer (Lab Vision, Fremont, CA,
USA). Positively stained cells were counted at 400 , and
the results were expressed as the percentage of each
population regarding the total number of interstitial infil-
trating cells.
2.4. RNA extraction and reverse transcription (RT)
Total RNA was isolated from frozen cores with the
‘‘Rneasy’’ kit (Qiagen, Chatsworth, CA) after homogenizat-
ing and sieving in Qiasredder columns (Qiagen). Reverse
transcription was done as previously described [12], using
random hexamers and SuperscriptR reverse-transcriptase
(Gibco BRL, Eggenstein, Germany), on samples treated
with RNAse-free DNAse I (Roche Diagnostics, Schweiz
Rotkreutz, Switzerland).
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For the specific amplification of isoforms Emk1A and
Emk1B we used a nested PCR approach with the following
primers:
Emk1Aup (5VTACCGGCGCCATGTCCAG),
Emk1Aup/nested
(5VGTTGGACTTACTGCTGGGCTTGG),
Emk1Bup (5VTCTCTCTGCTAGTGGTGGTTTCGG),
Emk1Bup/nested (5VCGACACCGTCCAGGTTCCC),
Emk1ABdown (5VGCTGAGTTGCGGCCCCGAATC),
Emk1ABdown/nested (GTTGGACTTACTGCTGGG-
CTTGG).
First PCR was performed using approx. 0.5 Ag of cDNA,
and 0.2 AM of each primer in the following conditions: 2
min at 94 jC, 35 cycles of 30 s at 94 jC, 30 s at 60 jC, 90 s
at 72 jC, and finally 10 min at 72 jC, using Taq polymer-
ase (Master Mix, PROMEGA Corp., Madison, WI, USA).
For the nested PCR, 1–5 Al of the first reaction were
amplified using the above ‘‘nested’’ primers at the same
conditions as first PCR, except that only 20 cycles were
performed.
For the specific amplification of exon 16, we used the
following primers:
Emk1/exon15 (5VCCCCTCCACGAACAGCGTCC),
Emk1/exon17 (5VAAGTTAGTTCGGTCTGGGGCTC).
Amplification was performed in the conditions described
above for the Emk1A/B first PCR. Over 10 Al of PCR
products were resolved in agarose gels and ethidium bro-
mide stained.
2.6. Statistical analysis
The Kolmogorov–Smirnov test was applied to analyse
the normal distribution of variables. Student’s t-test was
used in normal variables, and Mann–Whitney U-test was
applied to those not following a normal distribution and to
ordinal variables. Differences between categorical data were
assessed using a 2 2 contingency table analysis and the
Fisher’s exact tests. Results are expressed as meanF stan-
standard deviation. All P values were two-tailed, and a P
value < 0.05 was considered significant.3. Results
We analysed Par1/Emk1 expression on 51 kidney pro-
tocol biopsies from 51 recipients at 234F 148 days after
transplantation. According to the gender, the population
studied was composed by 34 males and 17 females, with a
mean age of 44F 15 years. Sample size distribution of the
51 biopsies, according to 1997 Banff criteria, was asfollows: 29 (56.9%) biopsies were adequate (z 10 glomer-
uli, z 2 arteries), 12 (23.5%) biopsies represented a
minimum sample adequacy (between seven and nine
glomeruli, and at least one arterial section), and 10 biopsies
(19.6%) were inadequate (between one and six glomeruli,
and at least one arterial section). Mean number of glomer-
uli in the biopsy cores processed for optical microscopy
was 11F 8, and all biopsies contained at least one arterial
section. Histological diagnoses, categorized according to
the Banff 97 schema, were the following: normal (n = 24),
borderline changes (n = 9), and CAN (n = 18). CAN was
mild (grade I) in 14 cases, moderate (grade II) in four
cases, and was associated with borderline changes in nine
cases. In addition, five diagnostic biopsies were also
analysed. Three of them were obtained from patients with
mild acute rejection, and the other two from patients with
mild chronic rejection.
3.1. Alternative splicing of the Emk1/Par1 transcript
generates Emk1/Par1 isoforms
We recently cloned the human form of ser/thr protein
kinase Emk1/Par1 [8]. RT-PCR analysis of Emk1/Par1
expression in a number of tissues showed the presence of
different isoforms originated by the usage of two putative
promoters and of an alternative exon (exon 16, see Fig. 1A)
[9]. Differential usage of the two promoters resulted in the
expression of two isoforms, Emk1A and Emk1B, that
differed only in their first exons at the 5V end (Fig. 1B).
Furthermore, regulated splicing of exon 16 originated other
two isoforms, one that included exon 16 (isoform Emk1D),
and another one lacking it (isoform Emk1E), that could be
detected as two bands (350 and 190 bp) when amplified
with flanking primers [9] (Fig. 1B). Expression analysis in
different tissues and cell lines, among them five samples
from nephrectomized kidneys, showed that all these iso-
forms were constitutively expressed, at similar steady-state
levels, in all samples tested. Representative samples of these
normal patterns of expression can be seen in Fig. 1: Emk1B
give a single band over 290 bp (see samples RP, BH, GP,
SA in Fig. 1C), and Emk1D and Emk1E a doublet of 190
and 350 bp, respectively (samples PM, MM, OC in Fig.
1D). No data is shown for Emk1A since no alterations in its
expression were found, and therefore it is not reported in
this work.
3.2. Alterations in the normal patterns of alternative
splicing of the Par1/Emk1 transcript in protocol biopsies
of renal allografts
We analysed the expression of the different Emk1 iso-
forms in the 51 patients enrolled in the study. When
analysing expression of exon 16, we found 43 samples
(84.4%) that co-expressed isoforms Emk1D and Emk1E,
i.e., which showed the pattern of expression previously
defined as normal. To confirm the nature of these bands,
Fig. 1. Splicing alterations of the Emk1/Par1 gene in human renal allografts. (A) Structure of the Emk1 gene and of its alternative splicing products. Boxes
show the different exons studied in this work. Solid lines represent introns, and dotted lines correspond to the splicing events detected in the Emk1 gene (exons
and introns are not drawn to scale). Exons are numbered as in the text. Arrows show the two predicted transcription origins and promoters. (B) Diagram of the
Emk1 isoforms studied in this work. Shown are the isoforms generated by splicing of alternative exons 2 and 16 (in red), and those generated by the use of the
Emk1A and Emk1B promoters (yellow and green). The length of the different exons is not drawn to scale. Emk1C shows the exon structure of the new Emk1
isoform detected in this study. (C) RT-PCR analysis of alternative splicing events of the Emk1 gene detected in representative allograft samples. Shown are the
bands encoding isoforms Emk1C, and Emk1B. Amplification of Emk1A is not shown since expression of this isoform was found to be constitutive, and no
expression changes were detected in the population studied. (D) RT-PCR analysis of alternative splicing events of the Emk1 gene detected in representative
allograft samples. Shown are the bands encoding isoforms Emk1D and Emk1E. Samples MP and MV show the alterations in the splicing patterns characterized
by the lack of isoforms Emk1D and Emk1E, respectively.
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random samples, and the sequences were shown to actually
correspond to the Emk1D and Emk1E. Strikingly, eight
other cases displayed alterations in the pattern of Emk1D/E
splicing that resulted in the complete lack of expression of a
single specific isoform. In this sense, Emk1D was not
detected in four samples, while Emk1E was lacking in
another four (see Fig. 1D for representative cases MP and
MV). No sample lacking both isoforms was detected among
our patients. When we analysed the diagnostic biopsies, the
same alterations were detected, with Emk1E lacking in one
of the two patients with chronic rejection and in one of the
three suffering acute rejection.
Expression of isoforms Emk1A and Emk1B was ana-
lysed by a nested PCR approach in two reactions. We used
two pairs of isoform-specific upstream primers and a
unique, common, pair of downstream primers in the fol-
lowing combinations; for Emk1A: Emk1Aup, Emk1AB-
down; and Emk1Aup/nested, Emk1ABdown/nested for the
nested amplification; for Emk1B: Emk1Bup, Emk1AB-
down; and Emk1Bup/nested, Emk1ABdown/nested for the
nested amplification (see Materials and methods). While
Emk1A was detected in all (51/51) the samples tested,
Emk1B was found only in 44 out of the 51 samples.
Nevertheless, we did not observe any histological lesion
significantly associated with the loss of Emk1B expression,
likely because the number of biopsies affected was too small
(7/51).3.3. A new, cryptic, exon is detected in Emk1/Par1
transcripts from protocol renal allograft biopsies
The most significant result obtained in this work was the
detection of a band of lower mobility than Emk1B in 10 out
of the 51 samples tested (see the upper band in sample HB
in Fig. 1C). Since this band (herein called Emk1C) had not
been previously detected, we cloned it and sequenced it. The
sequence of Emk1C was then compared with the draft of the
human genome where it was shown to correspond to the
known Emk1B plus an extra exon (herein called exon 2)
inserted at the precise boundaries of exons 1B and 3 (see
Fig. 1B), and showing canonical splice sites (data not
shown). Furthermore, when the sequence of exon 2 was
used to search the EST database at the GenBank no
significant hits were detected, so confirming that this
sequence actually corresponded to a cryptic exon not
usually expressed, as expected from our inability to detect
it in cell lines and tissues from different origins (data not
shown). Splicing of this cryptic exon originated two iso-
forms: one without exon 2 (the already known Emk1B) and
a new one that included exon 2 and was called Emk1C (see
Fig. 1A, B). After testing the 51 samples, we found that 10
allografts co-expressed isoforms, B and C, other 34 allog-
rafts expressed only isoform B, and in seven cases neither
isoforms were expressed and only Emk1A was detected.
Regarding biopsies performed for graft dysfunction, we
observed Emk1C[+] expression in one of the samples with
Table 2
Severity of acute and chronic lesions, according to the Banff 97 schema,
associated to the ‘‘de novo’’ presence of exon 2 in Emk1 (isoform
Emk1C[+]) in renal allograft protocol biopsies
Lesion type Emk1C[+] Emk1C[ ] P
N 9 34
g 0.22F 0.44 0.11F 0.40 ns
i 0.88F 0.33 0.41F 0.50 0.01
t 0.55F 0.52 0.29F 0.46 0.14
v 0 0 ns
ah 0.22F 0.44 0.26F 0.51 ns
cg 0.33F 0.50 0.23F 0.43 ns
ci 0.66F 0.70 0.29F 0.52 0.09
ct 0.55F 0.72 0.29F 0.46 ns
cv 0.11F 0.33 0.14F 0.50 ns
Emk1 isoforms are defined as follows (see also Fig. 1B): Emk1C[+],
presence of isoform with exon 2; Emk1C[ ], absence of isoform with
exon 2.
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(not shown).
3.4. Protocol biopsies of Emk1C[+] patients show a higher
extension of interstitial mononuclear cell infiltration
Co-expression of splicing isoforms D and E was the most
commonly found pattern, both in allografts (84.4%) and in
normal kidneys (100%), without any significant difference
in their prevalence rates. Consequently, there were very few
samples not co-expressing both forms: four (7.8%) that
displayed only isoform E (i.e. Emk1D was not detected),
and four others (7.8%) that were homozygous for Emk1D
and did not express Emk1E. We did not observe any
histological lesion significantly associated with the changes
in the splicing pattern of exon 16, likely because the number
of biopsies expressing a unique isoform was too small,
although we detected a tendency to a greater progress of
renal lesions among allografts from Emk1D[  ]E[+], to
Emk1D[+]E[ ] (Table 1).
We then analysed splicing of cryptic exon 2 (Emk1C) in
the homogeneous group of 43 biopsies that co-expressed
isoforms Emk1D and Emk1E (expression of cryptic exon 2
was detected in only one Emk1D[  ] patient, but in none of
the Emk1E[  ] patients). Depending on the presence or
absence of cryptic exon 2, these patients were grouped in
other two categories: Emk1C[+] (9 patients) and Emk1C[  ]
(34 patients). When we analysed the type of lesions present in
the biopsies from the Emk1C[+] and Emk1C[ ] subgroups,
we observed that extension of mononuclear cell interstitial
infiltration was higher in Emk1C[+] than Emk1C[ ] patients
(Table 2). Moreover, the degree of inflammation seemed to
be also more severe in Emk1C[+] allografts, because there
was a trend to display more infiltrating mononuclear cells in
the tubular epithelium. Furthermore, after studying the 51Table 1
Severity of acute and chronic lesions (defined according to the Banff 97
schema) associated with the presence or absence of exon 16 in Emk1
isoforms in renal allograft protocol biopsies
Lesion type Emk1D[+]E[+] Emk1D[ ]E[+] Emk1D[+]E[ ] P
N 43 4 4
g 0.14F 0.41 0.25F 0.50 0 ns
i 0.51F 0.51 0.50F 0.58 1.00F 0.00 ns
t 0.35F 0.48 0.25F 0.50 0.75F 0.50 ns
v 0 0 0 ns
ah 0.26F 0.49 0 0 ns
cg 0.26F 0.44 0 0 ns
ci 0.37F 0.58 0.25F 0.50 0.75F 0.96 ns
ct 0.35F 0.53 0.25F 0.50 0.75F 0.96 ns
cv 0.14F 0.47 0 0 ns
Emk1 isoforms are defined as follows (see also Fig. 1B): Emk1D[+],
presence of isoform with exon 16; Emk1D[ ], absence of isoform with
exon 16; Emk1E[+], presence of Emk1 isoform not having exon 16;
Emk1E[ ], absence of Emk1 isoform not having exon 16.
Abbreviations are: g, glomerulitis; i, interstitial infiltrate; t, tubulitis; v,
vasculitis; ah, arteriolar hyalinosis; cg, chronic glomerular lesion; ci, chronic
interstitium lesion; ct, chronic tubuli lesion; cv, chronic vascular lesion.protocol biopsies, we observed that those with borderline
inflammation also presented a more severe interstitial fibrosis
(0.57F 0.69 in 28 allograft biopsies with inflammation vs.
0.17F 0.38 in 23 allografts without inflammation,
P= 0.022), and a more severe tubular atrophy (0.53F 0.63
in 28 allograft biopsies with inflammation vs. 0.17F 0.38 in
23 allografts without inflammation, P= 0.025). In addition,
we noticed an increase in interstitial scarring in Emk1C[+]
patients, although this finding did not reach statistical sig-
nificance (Table 2).
Considering the diagnostic categories defined by the
Banff schema, we examined the prevalence of Emk1C[+]
among patients with borderline inflammation with fibrosis
(three out of nine), without fibrosis (two out of nine), and
with fibrosis without inflammation (two out of nine).
Although the proportion of Emk1C[+] was higher in patients
with borderline inflammation with fibrosis than in the other
groups (33% vs. 22%) or than in normal allografts (12.5%),
this result did not reach statistical significance due to the
small number of Emk1C[+] patients.
We studied the phenotypes of graft-infiltrating cells in
biopsies of Emk1C[+] and Emk1C[ ] patients available for
immunohistochemical analysis (n = 7 and n = 31, respective-
ly). After staining for CD3 (T lymphocytes), CD20 (B
lymphocytes) and CD68 (monocytes and macrophages),
we observed that the two groups of biopsies displayed
similar proportions of the three cell lineages: 50F 10% of
CD3+ cells, 20F 6% of CD20+ cells, and 30F 10% of
CD68+ cells in the group of Emk1C[+]patients vs. 49F 11%
of CD3 + cells, 21F14% of CD20+ cells and 30F 12% of
CD68+ cells in the group of Emk1C[  ]patients.
3.5. Clinical variables in Emk1C[+] patients
Demographic characteristics of patients are summarised
in Table 3. At the time of the protocol biopsy, Emk1C[+]
patients displayed a higher MAP (110F 11 vs. 99F 11 mm
Hg, P= 0.012), and presented a trend towards the use of
Table 3
Clinical characteristics of Emk1D[+]/E[+] allografts at baseline, grouped
according to the expression/lack of expression of exon 2 (Emk1C[+] vs.
Emk1C[ ]) in renal allograft protocol biopsies
Emk1C[+] Emk1C[ ] P
N 9 34
Donor age (years) 36F 17 44F 15 ns
Recipient age (years) 48F 10 50F 10 ns
Recipient sex (male/female) 7/2 23/11 ns
Number of transplant (1st, 2 d) 8/1 26/8 ns
PRA>20% 2 (22%) 8 (23%) ns
HLA mismatches 3.11F1.61 2.88F 1.17 ns
CIT (hours) 22F 4 22F 5 ns
ATN (no/yes) 9/0 29/5 ns
Acute rejection (no/yes) 6/3 29/5 ns
Mean CsA dose (mg/kg/d) 5.44F 1.51 5.78F 1.46 ns
Mean CsA levels (ng/ml) 204F 67 225F 57 ns
MMF (no/yes) 7/2 25/7 ns
Emk1 isoforms are defined as follows (see also Fig. 1B): Emk1C[+],
presence of the Emk 1 isoform that express exon 2; Emk1C[ ], absence of
Emk1 isoform with exon 2.
Abbreviations are: CIT, cold ischemia time; PRA, panel reactive antibodies;
ATN, acute tubular necrosis; CsA, cyclosporine; MMF, mycophenolate
mofetil treatment.
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mean number of antihypertensive drugs per day; P= 0.09).
There were no differences among serum creatinine levels
(155F 60 Amol/l in Emk1C[+] patients vs. 144F 40 Amol/
l in Emk1C[  ] patients, P= ns), or proteinuria (0.39F 0.29
g/day in Emk1C[+] patients vs. 0.27F 0.20 g/day in
Emk1C[ ] patients, P= ns). Regarding to immunosuppres-
sion, the different groups of treatment were homogeneous,
and there were not significant differences among them.
Graft function was followed for 55F 23 months. In this
time period, four patients lost their grafts, one due to a ‘‘de
novo’’ glomerulonephritis in the Emk1C[  ] group 24
months after transplantation, and three other patients died
with a functioning graft, one in the Emk1C[  ] group and
two in the Emk1C[+] group. Death of the Emk1C[ ] patient
was due to a carcinoma of the lung over 47 months after
renal transplantation. The two Emk1C[+] patients died of
acute myocardial infarction, and of multiple myeloma, 27.7
and 31.2 months after transplantation, respectively.4. Discussion
Ser/thr protein kinase Emk1/Par1 has been identified as a
key regulator of immune system homeostasis [7]. In this
paper, we report the detection of alterations in the splicing
pattern of the Emk1/Par1 gene in early protocol biopsies of
kidney allografts. Furthermore, we also demonstrate the
association among one of these splicing alterations, the
expression of a cryptic exon that originates Emk1C, a new
Par1/Emk1 isoform not previously described, with an in-
crease in the extension of interstitial infiltrates. These
Emk1C[+] patients also displayed a trend towards a more
severe interstitial fibrosis, already detected in early protocolbiopsies, and a higher MAP. These data extend the span of
expression alterations detected in deteriorating kidney allog-
rafts to the control of alternative splicing, and suggest a new
molecular mechanism that might be involved in CAN
pathogenics.
It has been suggested that silent graft inflammation has a
role in CAN development [1,13], in part due to the obser-
vation that interstitial mononuclear cell infiltrates in proto-
col biopsies from well-functioning grafts correlated with
graft dysfunction [14,15], and with a worsening of the CAN
grade in sequential protocol biopsies [16]. In this sense,
Lipman et al. [4] described a progressive increase in the
expression of immune activation genes proportional to the
severity of inflammatory lesions in protocol biopsies. Fur-
thermore, these authors demonstrated the existence of a
threshold for the expression of immune-activation genes,
particularly of cytotoxic T lymphocyte effectors, among
acute sub-clinical and acute clinical rejection, and suggested
that even inflammatory borderline changes could play a role
in graft degeneration [4]. This hypothesis has been further
supported by Kirk et al. [17], who established the associa-
tion among graft expression of pro-inflammatory cytokines,
and of other gene products related to T lymphocyte antigen
recognition, with a worsening of allograft function in
clinically stable biopsies. Moreover, Rush et al. [2] showed
that early treatment of sub-clinical rejection, diagnosed by
means of protocol biopsies, resulted in a better outcome of
the graft, with less scarring lesions.
Data from the Emk1 / knock-out mice indicated that
protein kinase Emk1 was required to keep CD4+ T cells in a
‘‘naı¨ve’’ state, and that loss of Emk1 resulted in their
inappropriate homing and activation in response to self or
environmental antigens [7]. In this sense, CD4+ T cells from
Emk1 / mice showed a deregulated surface expression of
CD44 and CD62L, while Th1 cells produced threefold more
IFN-g than their wild-type littermates upon activation
through the TCR, indicating that these cells were more
easily and potently activated by antigens [7]. These func-
tional alterations resulted in the lymphocyte infiltration of
kidneys of Emk1 / mice, among other organs, probably
due to the loss of their cell ‘‘homing’’ potential. In addition,
it was also observed that heterozygous Emk1+/  mice
displayed alterations of the immune system, although less
severe, suggesting that even partial Emk1 deficits could
alter immune homeostasis.
The major alterations in gene expression found in this
work have been the detection of a splicing shift that resulted
in the unbalanced expression of isoforms Emk1D and
Emk1E, as well as the finding of a cryptic exon whose
presence in the Emk1 transcript was significantly associated
with an increase in the extension of the interstitial infiltrate
of mononuclear cells in early and clinically stable renal
allograft biopsies. Although we are aware that expression of
the splicing isoform Emk1C could be a consequence of the
increase in the number of mononuclear cells in the renal
allografts, thus allowing the detection of transcripts usually
M. Hueso et al. / Biochimica et Biophysica Acta 1689 (2004) 58–6564expressed at very low levels, we think that it could actually
be due to a de-regulation of the splicing machinery. We
favour this last hypothesis since levels of Emk1A and
Emk1B were not raised in the samples expressing Emk1C
(see Fig. 1C) as would be expected if the effect was
uniquely due to the number of infiltrating cells; Emk1C
was not detected in all samples with interstitial infiltration;
we also detected an aberrant splicing of Emk1D/Emk1E in
8/51 biopsies; and, finally, because the sequence of exon 2
is not present in any of the databases of expressed gene
products, either ESTs or full-length transcripts, further
suggesting that it is actually a cryptic exon usually not
expressed.
We have also characterized the phenotype of graft-
infiltrating cells, but did not observe a cell type predominant
in the infiltrates of the patients positive for the splice variant
Emk1C, a fact in agreement with data derived from the
mouse knock-out model. In Emk / mice, lymphocyte
infiltrates consisted of a mixture of cell types accumulated
in the perivascular regions of the cortex and medulla of the
kidney, suggesting that changes in Emk levels (or in the
ratio of isoform expression) would cause a general, not
lineage restricted, defect in mononuclear cell adhesion and/
or homing [7]. Alternatively, these alterations could also be
due to changes in the repertoire of surface molecules in the
cells of kidneys. In this sense, Emk has been shown to
regulate cell-to-cell adhesion by controlling, at least, the
sorting of E-cadherin to the basolateral surface of epithelial
kidney cells [18].
Changes in alternative splicing can be caused by muta-
tions in the cis-acting signals that control the correct
elimination of introns, in which case only the mutated gene
would be affected, or, alternatively, they can be originated
by an unbalance in the activity of the splicing trans-acting
factors that regulate the process (see Refs. [19,20] for
reviews). Should this last be the case, one would expect
this would have a pleiotropic effect on other many genes
that depended on the balance of activities of splicing factors
to accurately process mRNA. This is an interesting point,
since methods for expression analysis (as DNA arrays) are
suited to detect quantitative variations, but tend to overlook
qualitative alterations as those affecting splicing.
We propose that changes in the expression pattern of the
Emk1 isoforms, as the ‘‘de novo’’ expression of Emk1C
here described, would generate protein variants that altered
lymphocyte properties as homing and/or activation. This
would eventually result in the infiltration of kidneys with a
population of activation-prone, longer resident lymphocytes,
with the subsequent disturbance of the immunological
homeostasis, the induction of inflammatory events in kidney
allografts, and the development of CAN.
In summary, we have detected splicing alterations of the
Emk1 transcript in protocol biopsies of kidney allografts.
One of these alterations generated a new Emk1 isoform
(Emk1C), whose expression was associated with a higher
degree of lymphocyte infiltration, with a trend to display amore severe interstitial fibrosis, as detected in early protocol
biopsies, and with a higher MAP, findings all of them
related to the development of CAN.Acknowledgements
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